BDM E

Drug Profile

BDM E

Alternative Names: Ala-glu-asp-gly - BioDiem; Alanyl glutamyl aspartyl glycine - BioDiem; BDM-E; Epitalon - BioDiem; Epitalon tetrapeptide - BioDiem; Epithalon - BioDiem; Epithalon tetrapeptide - BioDiem

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Bioregulation and Gerontology
  • Developer BioDiem; Monash University; University of Cambridge; University of Wisconsin at Milwaukee
  • Class Eye disorder therapies; Oligopeptides; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes
  • Available For Licensing Yes - Retinitis pigmentosa

Highest Development Phases

  • Phase I/II Diabetic macular oedema
  • Preclinical Age-related macular degeneration; Retinitis pigmentosa; Retinopathy of prematurity

Most Recent Events

  • 23 Sep 2015 BioDiem is still seeking licensees to enable the continued development of BDM E for Retinal diseases
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 09 Sep 2010 BDM E is available for licensing in USA for Retinitis pigmentosa as of 09 Sep 2010. www.biodiem.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top